Skip to content
Clinical Trials – home

Istituto Ortopedico Rizzoli

Verified siteinfo

Italy Via Giulio Cesare Pupilli 1, 40136 Bologna, Italy

  • 11 trials recruiting
  • Chondrosarcoma · Soft tissue sarcoma · Axial spondyloarthritis
  • Adults and children

About Specializations

Istituto Ortopedico Rizzoli in Bologna, Italy specialises in clinical trials of conditions such as Chondrosarcoma, Soft tissue sarcoma, Axial spondyloarthritis, Ewing's sarcoma, and other specialisations. This site conducts important research.

Main research areas of the site

Musculoskeletal Diseases and Orthopedic Regeneration

At Istituto Ortopedico Rizzoli in Bologna, clinical trials in musculoskeletal diseases focus on conditions that affect bones, joints, and connective tissues, with a strong emphasis on osteogenesis imperfecta, osteosarcoma, and challenging fracture healing.

  • Testing new treatments for brittle bone disease and reducing fracture risk in osteogenesis imperfecta
  • Evaluating therapies for delayed union and non-union long bone fractures to improve bone repair
  • Studying treatment approaches for osteosarcoma and other high-risk bone sarcomas

This research area aims to improve healing, strengthen bone outcomes, and support better long-term function for patients with complex orthopedic conditions.

Sarcoma and Rare Bone Cancer Research

A major part of the site’s work is dedicated to neoplasms, especially rare and aggressive cancers such as leiomyosarcoma, chondrosarcoma, Ewing sarcoma, and soft tissue sarcoma.

  • Assessing new anticancer therapies for advanced or metastatic sarcomas
  • Comparing treatment strategies to improve survival and disease control in leiomyosarcoma
  • Studying options for refractory or recurrent Ewing sarcoma and other difficult-to-treat sarcomas

The goal is to find more effective and better-tolerated treatments for patients with rare cancers that often have limited standard options.

Targeted and Immune-Based Oncology Studies

The Research, Innovation and Technology Department also supports trials exploring targeted and immune-based approaches for advanced cancers, including tenosynovial giant cell tumor, desmoid tumors, and selected sarcoma subtypes.

  • Testing targeted therapies designed to slow or stop tumor growth
  • Evaluating immune-focused treatments for advanced solid tumors
  • Measuring whether new combinations can improve tumor response and progression control

These studies are aimed at expanding treatment choices and improving outcomes for patients with hard-to-treat tumors.

Inflammatory and Immune System Conditions

The site also conducts research in immune system diseases, with attention to non-radiographic axial spondyloarthritis and related inflammatory conditions that can cause pain, stiffness, and reduced mobility.

  • Evaluating medicines that help maintain remission and prevent disease flare-ups
  • Studying how well treatments control inflammation over time
  • Supporting better symptom management and quality of life in chronic immune-mediated disease

This work seeks to improve long-term disease control while reducing the burden of persistent inflammation for patients.

Advanced Orthopedic and Connective Tissue Innovation

Research at Istituto Ortopedico Rizzoli also extends to skin and connective tissue diseases and advanced orthopedic innovation, reflecting the center’s interest in tissue repair, structural recovery, and supportive care.

  • Exploring therapies that may improve connective tissue healing and recovery
  • Assessing treatment effectiveness in complex orthopedic and tumor-related conditions
  • Investigating ways to improve diagnostics, response assessment, and patient outcomes

This broad research activity connects laboratory insight with clinical care, helping advance treatment for patients with rare and difficult musculoskeletal disorders.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Via Giulio Cesare Pupilli 140136 BolognaItaly
Recruiting now
11 trials
Conditions studied
25
Partner status
Verified site

More sites in BolognaItaly

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

26 clinical trials

Osteosarcoma

Recruiting

Cabozantinib Maintenance Therapy vs Best Supportive Care in Osteosarcoma Patients in Complete Remission or with Residual Disease after First‑Line Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Institut Gustave Roussy

Desmoid tumour

Recruiting

Study of nirogacestat in adult premenopausal women with desmoid tumors and aggressive fibromatosis to evaluate ovarian function recovery

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Nirogacestat Hydrobromide
  • Sponsor:Springworks Therapeutics Inc.
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic bone marrow-derived mesenchymal stromal cells, from selected donors
  • Sponsor:Fundacion Para La Investigacion Biomedica Del Hospital Universitario Puerta De Hierro Majadahonda

Study on Losartan and Hydrochlorothiazide for Osteogenesis Imperfecta in Patients Aged 16 and Above

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Hydrochlorothiazide
  • Sponsor:Istituto Ortopedico Rizzoli

Study on the Effectiveness of Denosumab with Chemotherapy (Cisplatin, Methotrexate, Doxorubicin) for Patients with Metastatic Osteosarcoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Cisplatin
  • Sponsor:Associazione Italiana Ematologia Oncologia Pediatrica

Study of drug combination therapy for patients with recurrent and primary refractory Ewing Sarcoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Anhydrous Docetaxel
  • Sponsor:The University Of Birmingham
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Istituto Ortopedico Rizzoli

Leiomyosarcoma+1

Recruiting

Study Comparing Trabectedin and Gemcitabine for Patients with Advanced or Metastatic Leiomyosarcoma After Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Italian Sarcoma Group

Chondrosarcoma

Recruiting

Study of ivosidenib in adults with advanced or metastatic chondrosarcoma with IDH1 mutation who are untreated or have had one prior treatment

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ivosidenib
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Chondrosarcoma+1

Recruiting

Study on Trabectedin for Adults and Young Adults with Advanced Mesenchymal Chondrosarcoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Trabectedin
  • Sponsor:Italian Sarcoma Group

Study on Infection Prevention in Joint Replacement Surgery Using Povidone, Chlorhexidine, and Vancomycin for Adult Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Benzyl Alcohol
  • Sponsor:Hamilton Health Sciences Corporation

Leiomyosarcoma+5

Not yet recruiting

Study on the Effectiveness and Safety of INT230-6 (Vinblastine Sulfate, Cisplatin) for Adults with Metastatic Soft Tissue Sarcomas

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Intensity Therapeutics Inc.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.